Article may be outdated

This article is 24 days old. Some details may have changed since publication.

Headlinne
Sign inGet Headlinne
The Hindu·2 min read·medium

Pfizer's prostate cancer drug combination gets U.S. FDA priority review

R
Reuters
Pfizer's prostate cancer drug combination gets U.S. FDA priority review
✦AI Summary

The U.S. FDA has granted priority review to Pfizer's application for a combination prostate cancer treatment using Talzenna and Xtandi. The treatment targets patients with metastatic castration-sensitive prostate cancer who have specific HRR gene mutations.

Why it mattersUnlock →

Pfizer said ​on Wednesday the U.S. Food ‌and Drug Administration ​has granted ⁠priority review to its application seeking expanded approval for ‌its prostate cancer treatment combination.

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
healthbusinessscience
Political bias analysisUnlock →
Read originalGet full access
✦

Get the full story

Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.

Create free account

Already have an account? Sign in